Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 08
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Sunshine Biopharma Inc
SBFM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.7000
0.30
75.92%
Ult. Agg.: Oct 8, 8:49 AM
$0.4610
0.0631
15.86%
Get Report
Panoramica
Notizie
Previsioni utili
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
PRO
Perché si muove?:
Sunshine Biopharma shares are trading lower after the company announced the...
Sunshine Biopharma Financials
Sunshine Biopharma (SBFM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY
Benzinga Newsdesk
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.
Vandana Singh
PRO
Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY
Benzinga Newsdesk
PRO
Sunshine Biopharma Q3 2024 GAAP EPS $(0.94), Sales $8.435M
Benzinga Newsdesk
PRO
Sunshine Biopharma Q2 EPS $(9.94) Misses $(0.37) Estimate, Sales $9.30M Beat $9.00M Estimate
Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(9.94) per share which missed the analyst consensus estimate of $(0.37) by 2586.49 percent. This is a 86.03 percent increase over losses of $(71.17) per
Benzinga Newsdesk
PRO
Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate
Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $(1.04) by 92.31 percent. This is a 75 percent increase over losses of $(8.00) per share from
Benzinga Newsdesk
